Acromegaly

What is Acromegaly?

Acromegaly is a rare hormonal disorder caused by excessive production of growth hormone, typically from a benign tumor in the pituitary gland. This condition leads to abnormal enlargement of bones and soft tissues, particularly in the hands, feet, and facial features. Acromegaly primarily affects adults between ages 40-60, with equal prevalence in men and women. The condition has an estimated prevalence of 40-125 cases per million people worldwide (ORPHA code 963).

Key statistics

Symptoms

**Common symptoms include:** enlarged hands and feet, facial changes, headaches, joint pain, excessive sweating, fatigue, sleep apnea, and vision problems.

**Early symptoms** often develop gradually and may be overlooked for years. Patients typically notice rings becoming too tight, shoes no longer fitting, or subtle changes in facial appearance. Headaches and excessive sweating are common early complaints that may be attributed to other causes.

**Progressive physical changes** become more apparent over time. The jaw may protrude (prognathism), causing dental problems and changes in bite. The nose, lips, and tongue enlarge, and skin becomes thick and oily. Hands and feet grow noticeably larger, with fingers becoming thick and sausage-like.

Submit Your Paper

**Serious complications** can develop without treatment. High blood pressure, diabetes, heart disease, and sleep apnea are common. Vision problems occur when pituitary tumors press against nearby structures. Joint pain and arthritis develop due to bone and cartilage overgrowth. Voice changes may occur due to enlarged vocal cords and sinuses.

Causes and risk factors

Acromegaly is caused by excess growth hormone production, most commonly (95% of cases) from a benign pituitary adenoma. These tumors develop spontaneously and are not inherited in most cases. Rarely, the condition results from tumors in other parts of the body that secrete growth hormone-releasing hormone.

**Genetic factors** play a role in some cases. Mutations in genes such as AIP (aryl hydrocarbon receptor interacting protein) can predispose individuals to pituitary adenomas. Familial cases may occur as part of multiple endocrine neoplasia syndromes or Carney complex.

**Risk factors** are largely unknown for sporadic cases. Family history increases risk slightly, and certain genetic syndromes predispose to pituitary tumors. Age is a factor, with most cases diagnosed in middle age, though the tumors may have been growing for years before diagnosis.

Prevention

Currently, there is no known way to prevent acromegaly, as most cases result from spontaneous pituitary adenomas. However, early detection through awareness of symptoms and regular medical checkups can help identify the condition sooner. For families with known genetic predispositions, genetic counseling and screening may be beneficial. Healthcare providers should maintain high clinical suspicion for acromegaly in patients presenting with characteristic features, even if subtle, to reduce diagnostic delays.

Complications

Without treatment, acromegaly leads to serious health complications and reduced life expectancy. **Cardiovascular complications** include cardiomyopathy, high blood pressure, and increased risk of heart disease, which are leading causes of death in untreated patients.

**Metabolic complications** include diabetes mellitus, which develops in 30-50% of patients due to growth hormone’s anti-insulin effects. **Respiratory problems** such as sleep apnea affect up to 80% of patients due to soft tissue overgrowth in the upper airway.

**Neurological complications** may occur when large pituitary tumors compress surrounding structures, causing vision loss, particularly peripheral vision defects. **Musculoskeletal problems** include severe arthritis and joint deformities that can be debilitating and irreversible.

**Cancer risk** may be increased, particularly for colorectal cancer, necessitating enhanced screening protocols.

Diagnosis

Diagnosis requires both clinical recognition and biochemical confirmation. **Blood tests** are essential, including measurement of insulin-like growth factor-1 (IGF-1), which remains elevated in acromegaly. An oral glucose tolerance test with growth hormone measurement confirms the diagnosis, as growth hormone fails to suppress normally after glucose administration.

**Imaging studies** using MRI of the pituitary gland identify and characterize pituitary adenomas in most cases. High-resolution MRI can detect tumors as small as 2-3 millimeters.

**Additional testing** may include visual field testing to assess for optic nerve compression, echocardiography to evaluate heart function, and colonoscopy due to increased cancer risk.

Early diagnosis is crucial because many complications, particularly joint deformities and cardiovascular changes, may be irreversible once established.

Treatment

Treatment aims to normalize growth hormone levels, reduce tumor size, and manage complications. **Surgery** is often the first-line treatment, with transsphenoidal resection being the preferred approach for most pituitary adenomas. Experienced neurosurgeons can achieve cure rates of 70-90% for smaller tumors.

**Medical therapy** is used when surgery is not curative or not feasible. Somatostatin analogs like octreotide and lanreotide are commonly prescribed and can effectively control growth hormone levels in many patients. Pegvisomant, a growth hormone receptor antagonist, is highly effective for normalizing IGF-1 levels.

**Radiation therapy** may be considered for persistent or recurrent tumors after surgery, though effects develop slowly over years. **Combination therapy** using multiple medications is sometimes necessary for optimal control.

Treatment requires ongoing monitoring and adjustment, as this is typically a lifelong condition requiring specialized endocrine care.

Prognosis

With appropriate treatment, life expectancy can approach normal, and quality of life can be significantly improved. Early diagnosis and treatment are associated with better outcomes and reduced complications.

**Treated patients** who achieve normal growth hormone and IGF-1 levels have substantially reduced cardiovascular risk and improved symptoms. However, some physical changes, particularly bone deformities, may be permanent.

**Untreated acromegaly** reduces life expectancy by 10-15 years, primarily due to cardiovascular and respiratory complications. The 10-year survival rate for untreated patients is approximately 75% compared to over 95% for adequately treated patients.

Long-term follow-up is essential, as some patients require treatment adjustments over time, and monitoring for complications must continue throughout life.

Quality of life

Living with acromegaly requires ongoing medical management and lifestyle adaptations. **Regular exercise** should focus on low-impact activities to protect joints affected by arthritis. Swimming and walking are often well-tolerated, while high-impact sports may worsen joint problems.

**Sleep management** is crucial, as sleep apnea is common. Continuous positive airway pressure (CPAP) therapy may be necessary. Maintaining a consistent sleep schedule and creating an optimal sleep environment can help.

**Dietary considerations** include managing diabetes if present and maintaining a heart-healthy diet. Regular meals and monitoring carbohydrate intake help stabilize blood sugar levels.

**Mental health support** is important, as the physical changes and chronic nature of the condition can affect self-esteem and social relationships. Counseling or support groups can be beneficial.

**Workplace accommodations** may be needed for those with joint problems or fatigue. This might include ergonomic workstations or flexible scheduling for medical appointments.

Pregnancy and fertility

Acromegaly can affect fertility in both men and women due to hormonal imbalances that may disrupt normal reproductive function. Women may experience irregular menstrual cycles, while men may have reduced testosterone levels.

**During pregnancy**, most medications used to treat acromegaly require careful evaluation. Octreotide and lanreotide have limited safety data in pregnancy, while pegvisomant is generally avoided.

**Pregnancy management** requires collaboration between endocrinologists and obstetricians. Some women may safely discontinue medications during pregnancy under close monitoring, as pregnancy hormones can sometimes improve symptoms temporarily.

**Genetic counseling** is recommended for patients with familial forms of acromegaly or associated genetic syndromes to discuss inheritance risks and family planning options.

Children

Acromegaly is extremely rare in children. When growth hormone excess occurs before growth plates close, it causes gigantism rather than acromegaly, characterized by excessive linear growth and tall stature.

**Pediatric presentation** includes rapid growth velocity, large hands and feet, and facial changes. Early diagnosis is crucial to prevent extreme tall stature and associated complications.

**Treatment considerations** in children are similar to adults but require pediatric endocrine expertise. Growth and development must be carefully monitored, and treatment goals include normalizing growth velocity while preserving normal pubertal development.

**School accommodations** may be needed for children with physical limitations or frequent medical appointments.

When to see a doctor

**Seek immediate medical attention** for sudden severe headaches, vision changes, or signs of pituitary apoplexy (sudden onset severe headache, visual disturbances, nausea, and vomiting).

**Schedule routine evaluation** if you notice gradual changes in appearance, particularly enlarging hands or feet, facial changes, or persistent headaches. Other concerning symptoms include excessive sweating, joint pain, fatigue, or snoring that worsens over time.

**Regular follow-up** is essential for diagnosed patients to monitor treatment effectiveness and screen for complications. This typically includes periodic blood tests, imaging studies, and cardiovascular assessments.

Regional context

GMJ welcomes contributions from regional researchers to build the evidence base for acromegaly in the Caucasus. Regional healthcare systems may benefit from increased awareness programs to reduce diagnostic delays, as the condition’s rarity and gradual onset often lead to misdiagnosis or delayed recognition.

Research and clinical trials

Current research focuses on developing new therapeutic agents, improving surgical techniques, and understanding long-term complications. **Novel medications** under investigation include new somatostatin analogs with improved efficacy and convenience.

**Genetic research** continues to identify new susceptibility genes and improve understanding of familial cases. **Quality of life studies** are examining optimal treatment strategies to minimize long-term complications.

Patients interested in clinical trials can search ClinicalTrials.gov for current studies. Participation in research helps advance understanding and treatment of this rare condition.

Frequently asked questions

Can acromegaly be cured?

Yes, surgical removal of pituitary adenomas can cure acromegaly in many patients, particularly those with smaller tumors. However, some patients require ongoing medical treatment to maintain normal hormone levels.

Is acromegaly hereditary?

Most cases are not inherited and occur sporadically. However, about 5% of cases have a genetic component, particularly those associated with multiple endocrine neoplasia syndromes or familial isolated pituitary adenomas.

How long does it take to diagnose acromegaly?

Unfortunately, diagnosis is often delayed 4-10 years from symptom onset because changes develop gradually and may be attributed to normal aging or other conditions.

Will treatment reverse the physical changes?

Some soft tissue changes may improve with treatment, but bone changes are typically permanent. Early diagnosis and treatment can prevent progression of deformities.

Can people with acromegaly live normal lives?

With proper treatment, most people with acromegaly can lead relatively normal lives with good quality of life, though ongoing medical management is necessary.

Support and resources

– **Orphanet**: https://www.orpha.net (comprehensive rare disease database)
– **NORD (National Organization for Rare Disorders)**: https://rarediseases.org
– **Acromegaly Community**: https://www.acromegalycommunity.com
– **Pituitary Network Association**: https://pituitary.org
– **European Reference Network on Rare Endocrine Conditions (Endo-ERN)**: https://endo-ern.eu
– **EURORDIS (European Organisation for Rare Diseases)**: https://www.eurordis.org

Related conditions

– Cushing’s Disease – Another pituitary adenoma causing hormone excess
– Prolactinoma – Benign pituitary tumor producing prolactin
– Multiple Endocrine Neoplasia – Genetic syndromes causing multiple hormone-producing tumors
– Carney Complex – Genetic syndrome associated with various tumors including pituitary adenomas
– Gigantism – Growth hormone excess occurring before growth plate closure in children

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.